Nature Biotechnology's annual survey of public biotechnology companies finds some attrition, but on the whole a stronger sector.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Van Brunt, J. Financing finally flows. Signals Magazine, Jan. 2004, http://www.signalsmag.com/signalsmag.nsf/.
Burrill, G.S. Biotech 2004: Back on Track (Burrill & Company, San Francisco, CA, 2004).
Ernst & Young. Refocus: The European Perspective Global Biotechnology Report 2004 (UK Health Sciences Group, Ernst & Young, Reading, UK, 2004).
Lähteenmäki, R. & DeFrancesco, L. Public biotechnology 2002—the numbers. Nat. Biotechnol. 21, 607–612 (2003).
Louët, S. IPO floodgates unlikely to open after Ark flotation. Nat. Biotechnol. 22, 367–368 (2004).
Kandachi, K. Japan's biotech sector shows signs of life. Nat. Biotechnol. 21, 1256–1257 (2003).
Bouchie, A. Companies jostle for access to public markets. Nat. Biotechnol. 21, 1413–1414 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lähteenmäki, R., Baker, M. Public biotechnology 2003—the numbers. Nat Biotechnol 22, 665–670 (2004). https://doi.org/10.1038/nbt0604-665
Issue Date:
DOI: https://doi.org/10.1038/nbt0604-665
This article is cited by
-
Insights into US public biotech sector using patenting trends
Nature Biotechnology (2006)
-
Public biotechnology 2004—the numbers
Nature Biotechnology (2005)